Unknown

Dataset Information

0

Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination.


ABSTRACT: Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at high risk of morbidity and mortality. Sacubitril valsartan (previously known as LCZ696) is a new oral agent approved for the treatment of symptomatic chronic heart failure in adults with reduced ejection fraction. It is described as the first in class angiotensin receptor neprilysin inhibitor (ARNI) since it incorporates the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan. Neprilysin is an endopeptidase that breaks down several vasoactive peptides including natriuretic peptides (NPs), bradykinin, endothelin and angiotensin II (Ang-II). Therefore, a natural consequence of its inhibition is an increase of plasmatic levels of both, NPs and Ang-II (with opposite biological actions). So, a combined inhibition of these both systems (Sacubitril / valsartan) may enhance the benefits of NPs effects in HF (natriuresis, diuresis, etc) while Ang-II receptor is inhibited (reducing vasoconstriction and aldosterone release). In a large clinical trial (PARADIGM-HF with 8442 patients), this new agent was found to significantly reduce cardiovascular and all cause mortality as well as hospitalizations due to HF (compared to enalapril). This manuscript reviews clinical evidence for sacubitril valsartan, dosing and cautions, future directions and its considered place in the therapy of HF with reduced ejection fraction.

SUBMITTER: Kaplinsky E 

PROVIDER: S-EPMC5253408 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5076745 | BioStudies
2016-01-01 | S-EPMC5013095 | BioStudies
2018-01-01 | S-EPMC6220559 | BioStudies
2020-01-01 | S-EPMC7768573 | BioStudies
1000-01-01 | S-EPMC5438418 | BioStudies
2018-01-01 | S-EPMC6267534 | BioStudies
2019-01-01 | S-EPMC6554586 | BioStudies
2020-01-01 | S-EPMC6984414 | BioStudies
2020-01-01 | S-EPMC7214374 | BioStudies
2016-01-01 | S-EPMC4800749 | BioStudies